What is Gujarat Terce Laboratories Ltd (524314) share price return in the past 10 years?

Gujarat Terce Laboratories Ltd share price has appreciated 14.7% annually (CAGR) over the past ten years.

What is the share price of Gujarat Terce Laboratories Ltd (524314)?

Company share prices are keep on changing according to the market conditions. The current trading price of Gujarat Terce Laboratories Ltd (524314) on 13-Aug-2026 16:59:59 at 16:59 is 37.04.

What is the P/E ratio of Gujarat Terce Laboratories?

The latest standalone P/E ratio of Gujarat Terce Laboratories as of 13-Aug-2026 is 13.80.

What is the P/B ratio of Gujarat Terce Laboratories Ltd (524314)?

The latest standalone P/B ratio of Gujarat Terce Laboratories Ltd (524314) as of 13-Aug-2026 is 3.02.

What is the 52-week high and low of Gujarat Terce Laboratories Ltd (524314)?

The 52-week high of Gujarat Terce Laboratories Ltd (524314) is Rs. 59.78 and the 52-week low is Rs. 29.00.

Gujarat Terce Laboratories Ltd (524314)

Name: Gujarat Terce Laboratories Ltd (524314)
Brand: Gujarat Terce Laboratories

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524314 NSE: Pharmaceuticals & Drugs | Small Cap | Gujarat Terce Labs. Share Price

₹37.04 -1.99 (-5.10%)

As on 13-Aug'26 16:59

Gujarat Terce Laboratories Ltd (524314)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524314 NSE: Pharmaceuticals & Drugs | Small Cap | Gujarat Terce Labs. Share Price

₹37.04 -1.99 (-5.10%)

As on 13-Aug'26 16:59

Key Metrics

Valuation Multiples

Market Cap

₹29 Cr.

Current Price

₹37

52-Week Low / High

₹29 / 60

TTM EPS

₹2.7

TTM Sales

₹45.6 Cr.

Book Value per Share

₹12.3

P/E Ratio

13.80

Higher than its 3-year historical median

Industry PE

53.4

Price to Book (P/B)

3.02

In line with its 5-year historical median

Price to Sales (P/S)

0.63

Higher than its 5-year historical median

EV/EBITDA

6.79

Lower than its 5-year historical median

Dividend Yield

Profitability Efficiency

Return on Equity (ROE)

27.77%

Outperforms industry median

Return on Capital Employed (ROCE)

34.83%

Outperforms industry median

Return on Assets (ROA)

9.52%

Operating Profit Margin

7.9%

Net Profit Margin

4.64%

Gross Profit Margin

8.2%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

-5.44%

Operating Profit Growth (1 Year)

-3.35%

Net Profit Growth (1 Year)

Asset Quality

Promoter Holding

40.03%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹2 Cr.

Equity

₹7.8 Cr.

Face Value

₹10

All Time Low / High

₹0.50 / 94.90

Gujarat Terce Laboratories stock performance

Key Ratios

Check Before You Invest

M-Cap below 100cr DeciZen not available

Q.1 Is Gujarat Terce Laboratories Ltd a good quality company?

Gujarat Terce Laboratories Ltd is a quality company, based on a multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Gujarat Terce Laboratories Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Gujarat Terce Laboratories Ltd vs industry peers?

Gujarat Terce Laboratories Ltd revenue CAGR is 13.52%, compared to the industry median CAGR of 5.68%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Gujarat Terce Laboratories Ltd?

Promoters hold 40.03% of the Gujarat Terce Laboratories Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Gujarat Terce Laboratories Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 14.7% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26	TTM
ROCE % ⓘ	1.9%	4%	5.4%	5.8%	-16.4%	8.3%	-14.8%	9.7%	41.4%	34.8%	-
Value Creation Index ⓘ	-0.9	-0.7	-0.6	-0.6	-2.2	-0.4	-2.1	-0.3	2.0	1.5	-
Growth Parameters ⓘ
Sales ⓘ	25.3	29	31	37.5	25.2	40.1	46.8	48	50.2	47.5	46
Sales YoY Gr.	-	14.7%	7%	21%	-32.9%	59.4%	16.6%	2.5%	4.7%	-5.4%	-
Adj EPS ⓘ	-0	0.2	0.6	0.4	-3.7	1.2	-2.3	0.3	-1.3	3.2	2.7
YoY Gr.	-	NA	141.7%	-36.2%	-1100%	NA	-294%	NA	-503%	NA	-
BVPS (₹) ⓘ	13.6	14	14.6	15	10.3	11.5	9.3	9.6	8.3	12.5	12.3
Adj Net Profit ⓘ	-0	0.2	0.4	0.3	-2.8	0.9	-1.7	0.2	-1	2.5	2
Cash Flow from Ops. ⓘ	0.2	4.6	-0.6	-1.6	-0.2	-0.4	0	2.6	3.1	1.7	-
Debt/CF from Ops. ⓘ	29	0.1	-1.1	-1.6	-29	-15.1	272.4	1.5	0.3	0.8	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	7.3%	13.5%	0.5%	-5.4%
Adj EPS ⓘ	NA	NA	NA	NA
BVPSⓘ	-0.9%	3.9%	10.5%	51.2%
Share Price	14.7%	19.8%	15.6%	-11.9%

Key Financial Parameters ⓘ

	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26	TTM
Return on Equity % ⓘ	-0.2	1.7	4.1	2.5	-29.3	10.6	-21.7	3.5	-14.5	30.5	21.7
Op. Profit Mgn % ⓘ	0.3	1.1	1.6	1.8	-10.3	2.8	-4.6	2.6	7.7	7.9	7.2
Net Profit Mgn % ⓘ	-0.1	0.6	1.4	0.7	-10.9	2.1	-3.6	0.5	-2	5.2	4.6
Debt to Equity ⓘ	0.7	0	0.1	0.2	0.6	0.8	1.1	0.5	0.2	0.1	-
Working Cap Days ⓘ	246	209	196	178	271	176	163	147	129	130	53
Cash Conv. Cycle ⓘ	146	94	59	60	98	62	48	34	30	42	8

Valuation of Gujarat Terce Labs. - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Financials

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Sales	25.29	29.01	31.03	37.54	25.18	40.13	46.78	47.97	50.20	47.47
Operating Expenses ⓘ +	25.21	28.69	30.54	36.86	27.95	39.02	48.95	46.71	46.31	43.72
Manufacturing Costs	0.37	0.52	0.68	0.97	0.72	1.55	1.72	1.43	2.20	1.60
Material Costs	9.66	10.52	11.53	13.17	9.67	14.34	18.19	16.65	17.47	16.35
Employee Cost	10.64	11.93	12.82	14.81	12.63	15.49	14.38	15.11	15.37	14.89
Other Costs ⓘ	4.54	5.73	5.51	7.91	4.93	7.63	14.67	13.52	11.27	10.89
Operating Profit ⓘ	0.08	0.32	0.49	0.68	-2.77	1.12	-2.16	1.27	3.88	3.75
Operating Profit Margin (%)	0.3%	1.1%	1.6%	1.8%	-11.0%	2.8%	-4.6%	2.6%	7.7%	7.9%
Other Income ⓘ +	0.44	0.41	0.32	0.29	0.80	0.31	0.35	0.32	0.31	0.34
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	-0.45
Interest ⓘ	0.31	0.23	0.25	0.29	0.39	0.40	0.72	0.68	0.42	0.18
Depreciation ⓘ	0.19	0.19	0.21	0.24	0.18	0.28	0.36	0.37	0.38	0.42
Profit Before Tax ⓘ	0.02	0.33	0.35	0.44	-2.53	0.75	-2.89	0.54	3.39	3.03
Tax ⓘ	0.04	0.05	-0.09	0.16	-0.01	-0.13	-1.22	0.30	4.37	0.83
Profit After Tax	-0.01	0.27	0.43	0.28	-2.52	0.87	-1.67	0.24	-0.98	2.20
PAT Margin (%)	-0.1%	0.9%	1.4%	0.7%	-10.0%	2.2%	-3.6%	0.5%	-2.0%	4.6%
Adjusted EPS (₹)	-0.0	0.4	0.6	0.4	-3.4	1.2	-2.3	0.3	-1.3	2.8
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Equity and Liabilities
Shareholders Fund +	10.06	10.40	10.83	11.11	7.66	8.53	6.86	7.11	6.13	9.73
Share Capital ⓘ	7.42	7.42	7.42	7.42	7.42	7.42	7.42	7.42	7.42	7.79
Reserves ⓘ	2.64	2.98	3.41	3.69	0.24	1.11	-0.56	-0.31	-1.29	1.94
Debt +	6.99	0.34	0.65	2.53	4.57	6.07	6.44	3.13	0.31	1.24
Long Term Debt	5.49	0.16	0.13	0.16	0.42	2.30	1.46	0.93	0.30	0.03
Short Term Debt	1.51	0.18	0.52	2.38	4.14	3.77	4.98	2.20	0.01	1.21
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	1.58	3.32	2.81	3.19	2.85	4.03	5.85	4.71	3.61	1.58
Others Liabilities ⓘ	5.02	5.40	5.04	5.51	6.62	8.46	7.85	7.10	12.34	11.30
Total Liabilities ⓘ	23.66	19.47	19.34	22.34	21.70	27.09	27	22.05	22.39	23.85
Fixed Assets
Net Fixed Assets ⓘ +	6.17	1.88	2.06	2.29	2.45	4.29	3.99	3.69	3.65	3.25
Gross Block	9.79	5.23	5.62	6.10	6.16	8.28	8.33	8.40	8.75	8.31
Accumulated Depreciation	3.62	3.35	3.56	3.80	3.71	3.99	4.35	4.71	5.10	5.06
CWIP ⓘ	0	0	0	0	0	0	0	0	0	0
Investments ⓘ	0.24	0.27	0.29	0.27	0.27	1.77	0.27	0.27	0.52	1.35
Inventories	3.97	3.79	3.78	3.43	3.74	6.43	4.43	3.93	3.68	3.73
Trade Receivables	7.92	4.58	4.53	7.01	5.17	5.47	7.99	5.66	5.07	4.87
Cash Equivalents	0.53	0.73	0.18	0.04	1.29	0.01	2.03	0.09	0.78	2.86
Others Assets ⓘ	4.82	8.21	8.50	9.30	8.77	9.11	8.30	8.41	8.70	7.80
Total Assets ⓘ	23.66	19.47	19.34	22.34	21.70	27.09	27	22.05	22.39	23.85

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Cash Flow From Operating Activity ⓘ +	0.24	4.58	-0.61	-1.59	-0.16	-0.44	0.03	2.60	3.06	1.71
PBT ⓘ	0.02	0.33	0.35	0.44	-2.52	0.75	-2.89	0.54	3.39	3.03
Adjustment ⓘ	0.08	0.05	0.22	0.25	0.57	0.60	1.02	0.76	0.53	0.38
Changes in Working Capital ⓘ	0.45	4.3	-1.04	-2.17	1.94	-1.69	1.94	1.29	-0.78	-1.69
Tax Paid ⓘ	-0.31	-0.10	-0.13	-0.10	-0.15	-0.10	-0.04	0	-0.08	0
Cash Flow From Investing Activity ⓘ +	0.18	1.11	-0.13	-0.27	-0.42	-2.37	0.62	-0.46	0.46	-0.11
Capex	-0.01	-0.13	-0.40	-0.48	-0.50	-2.11	-0.06	-0.07	0.35	-0.02
Net Investments	0.06	-0.19	-0.02	0.02	-0.02	-1.50	-0	-0	-0.24	-0.84
Others ⓘ	0.14	1.43	0.28	0.19	0.10	1.25	0.68	-0.39	0.35	0.75
Cash Flow From Financing Activity ⓘ +	-0.36	-5.49	0.20	1.72	1.83	1.53	-0.12	-4.08	-2.83	0.47
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	1.05
Net Proceeds from Borrowing ⓘ	-0.05	-5.17	0.11	0.16	0.37	1.88	-0.84	-0.53	-0.74	-0.84
Interest Paid ⓘ	-0.31	-0.23	-0.25	-0.29	-0.28	-0.40	-0.72	-0.68	-0.42	-0.18
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-0	-0.09	0.34	1.85	1.74	0.06	1.44	-2.87	-1.67	0.44
Net Cash Flow ⓘ	0.06	0.20	-0.55	-0.14	1.24	-1.28	0.52	-1.94	0.69	2.08

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Ratios
ROE (%)	-0.15	2.65	4.07	2.52	-26.85	10.77	-21.71	3.49	-14.79	27.77
ROCE (%)	1.93	3.96	5.38	5.77	-16.4	8.31	-14.81	9.72	41.39	34.83
Asset Turnover Ratio	1.05	1.35	1.6	1.8	1.14	1.65	1.73	1.96	2.26	2.05
PAT to CFO Conversion(x)	N/A	16.96	-1.42	-5.68	N/A	-0.51	N/A	10.83	N/A	0.78
Working Capital Days
Receivable Days	118.30	78.60	53.60	56.10	88.30	48.40	52.50	51.90	39	38.20
Inventory Days	59.50	48.80	44.50	35.10	52	46.30	42.40	31.80	27.70	28.50
Payable Days	75.70	85.10	97.10	83.20	113.90	87.50	99.10	115.80	87	58

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Gujarat Terce Laboratories Ltd FAQs

The current trading price of Gujarat Terce Labs. on 13-Aug-2026 16:59 is ₹37.04.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 12-Aug-2026 the market cap of Gujarat Terce Labs. stood at ₹28.86 Cr

The latest P/E ratio of Gujarat Terce Labs. as of 12-Aug-2026 is 13.80.

The latest P/B ratio of Gujarat Terce Labs. as of 12-Aug-2026 is 3.02.

The 52-week high of Gujarat Terce Labs. is ₹59.78 and the 52-week low is ₹29.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Gujarat Terce Labs. is ₹45.62 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Gujarat Terce Laboratories Ltd is a below average quality company.

The key valuation ratios of Gujarat Terce Laboratories Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Gujarat Terce Laboratories Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Gujarat Terce Laboratories Ltd

Gujarat Terce Laboratories is engaged in the manufacturing of tablets, capsules, syrup and injections pertaining to the product group, pharmaceutical formulations and ayurvedic medicines. The company is selling its product in the domestic as well as international market.

The companyâ€™s registered office and factory are located at Bileshwarpura, Gandhinagar in Gujarat. Installed capacity of the company is 270 million tablets and 108 million capsules per annum.

Product list of the company includes:

Tablets
Capsules
Syrup
Injections

You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Compliance Officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com	Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com	Telephone: +919860919463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com	Telephone: +919175899463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Gujarat Terce Laboratories Ltd (524314)

Gujarat Terce Laboratories Ltd (524314)

Gujarat Terce Laboratories stock performance

Check Before You Invest

M-Cap below 100cr DeciZen not available

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Valuation of Gujarat Terce Labs. - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Financials

Equity and Liabilities

Fixed Assets

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Gujarat Terce Laboratories Ltd FAQs

About Gujarat Terce Laboratories Ltd

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Gujarat Terce Laboratories Ltd (524314)

Gujarat Terce Laboratories Ltd (524314)

Gujarat Terce Laboratories stock performance

Check Before You Invest

M-Cap below 100cr DeciZen not available

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Valuation of Gujarat Terce Labs. - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Financials

Equity and Liabilities

Fixed Assets

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Gujarat Terce Laboratories Ltd FAQs

What is the share price of Gujarat Terce Labs.?

What is the market cap of Gujarat Terce Labs.?

What is the P/E ratio of Gujarat Terce Labs.?

What is the P/B ratio of Gujarat Terce Labs.?

What is the 52-week high and low of Gujarat Terce Labs.?

What is the TTM revenue of Gujarat Terce Labs.?

Is Gujarat Terce Laboratories Ltd a good quality company?

Is Gujarat Terce Laboratories Ltd undervalued or overvalued?

Is Gujarat Terce Laboratories Ltd a good buy now?

About Gujarat Terce Laboratories Ltd

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.